---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-22-000042"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:27:35.956131+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "medium"
source: SEC EDGAR
---

# Maravai Q2 revenue $242.7M (+11% YoY), net income $156.7M (+17%), Adj. EBITDA margin 78% record

## Summary
- Q2 revenue $242.7M (+11% YoY); net income $156.7M (+17%); Adj. EBITDA $188.5M (78% margin).
- Nucleic Acid Production revenue $225.2M (+17% YoY); base business (ex-COVID CleanCap) grew 27%.
- Biologics Safety Testing revenue $17.5M (-4% YoY); Protein Detection business sold in Sept 2021.
- Leadership additions: Pete Leddy as EVP/CAO, Kate Broderick SVP R&D, Jay Lochhead VP Quality & Regulatory.
- Signed DoD cooperative agreement to partly fund Nucleic Acid Production manufacturing expansion in San Diego.

## SEC filing metadata
- accession: 0001823239-22-000042
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323922000042/0001823239-22-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323922000042/mrvi-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-22-000042
- JSON: https://secwatch.observer/filing/0001823239-22-000042.json
- Plain text: https://secwatch.observer/filing/0001823239-22-000042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.